For example, it has been shown that artificially activating NHE1 activity by modulating regulation of the protein accentuates the damage the protein causes in pathology in the heart [59,81,82,83,84] and in breast cancer [46,85,86]—two common diseases. Here, SLC9A1 is linked to breast carcinoma.